2015 Annual Meeting

Pulmonary Pathology Society

2015 Annual Meeting

Room CC Ballroom C, March 21 2015, 7:00pm to 10:00pm

Aliya Husain, Lida Hariri, Kevin Leslie, Philip Cagle, Mari Mino-Kenudson, Lynette Sholl, Bryce P. Portier, Kirtee Raparia, Keith Kerr, Natasha Rekhtman, Fred Hirsch

New Developments in Lung Cancer Predictive Biomarkers.

Educational Objective

Multiple new developments in lung cancer predictive biomarkers have occurred over the past year, introducing new knowledge and changes in clinical practices for pathologists. There is an urgent need to update pathologists on recent advances in predictive biomarkers of lung cancer. The two clinically validated and Food and Drug Administration approved lung cancer predictive biomarkers (epidermal growth factor receptor mutations and anaplastic lymphoma kinase (ALK) translocations) occur in only about 20% of lung adenocarcinomas and acquired resistance develops to first generation drugs. Several other oncogenic drivers for lung adenocarcinoma have emerged as potentially druggable targets with new predictive biomarkers. Oncologists are requesting testing for ROS1 translocations which predict susceptibility to crizotinib, already approved for ALK positive lung cancers. Other potential biomarkers which are currently undergoing clinical trials are RET, MET, HER2 and BRAF. These five biomarkers are under consideration for inclusion in revised lung cancer biomarker guidelines by the College of American Pathologists, International Association for the Study of Lung Cancer and Association for Molecular Pathology. Screening by immunohistochemistry may be useful for some biomarkers (ALK, ROS1, BRAF) and immunohistochemistry may serve as the biomarker for targeted therapy in some instances (MET, EGFR). Targeted next generation sequencing techniques may be useful as well. In particular, new next generation techniques such as anchored PCR allow for detection of translocations without the need for cytogenetic techniques. The Pulmonary Pathology Society Council and its Programme Committee discuss all meeting programmes, the final programme drawn up by the Programme Committee being ratified by Council. Target audience includes practicing community and academic pathologists, residents and fellows in pathology. Upon completion of this educational activity, participants should be able to:

  1. identify new lung cancer biomarkers and implications for daily practice
  2. apply lung cancer biomarker immunohistochemistry to daily practice for efficacy and cost reduction
  3. understand techniques, benefits and limitations of cytology specimens for lung cancer biomarker testing
  4. recognize the advantages of next generation sequencing for testing of lung cancer biomarker translocations

Session Credits: CME = 3 / SAMs = N/A


Speaker: Kevin O. Leslie, MD, Mayo Clinic- Arizona, Scottsdale, AZ
Handouts: View PDF
Companion Meeting Moderator
Speaker: Lida Hariri, MD, PhD, Massachusetts General Hospital, Boston, MA
Companion Meeting Moderator
Speaker: Aliya N. Husain, MD, University of Chicago Hospital, Chicago, IL
Introduction: Overview of Current Status of Lung Cancer Predictive Biomarkers
Speaker: Philip T. Cagle, MD, The Methodist Hospital, Houston, TX
Handouts: View PDF
Translocations as Predictive Biomarkers in Lung Cancer: Overview
Speaker: Mari Mino-Kenudson, MD, Massachusetts General Hospital, Boston, MA
Handouts: View PDF
Translocation Screening with Immunohistochemistry
Speaker: Lynette M. Sholl, MD, Brigham and Women's Hospital, Boston, MA
Handouts: View PDF
Translocation Testing by Next Generation Sequencing
Speaker: Bryce P. Portier, MD, PhD, MD Anderson Cancer Center, Houston, TX
Handouts: View PDF
Mutations as Predictive Biomarkers in Lung Cancer: Overview
Speaker: Kirtee Raparia, MD, Northwestern University, Chicago, IL
Handouts: View PDF
Role of Immunohistochemistry in Mutation Testing
Speaker: Keith M. Kerr, MBChB, Aberdeen University School of Medicine, Aberdeen, Scotland
Handouts: View PDF
Predictive Biomarker Testing in Cytology and Small Biopsy Specimens
Speaker: Natasha Rekhtman, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY
Handouts: View PDF
Interface of Oncology and Pathology in Targeted Therapy of Lung Cancer
Speaker: Fred Hirsch, MD, PhD, University of Colorado Cancer Center, Aurora, CO
Handouts: View PDF


view more